

13. WHO. Report of the Independent Monitoring Board of the Global Polio Eradication Initiative, November 2012. Available at: http://www.polioeradication.org/Portals/0/Document/Governance/IMB/7IMBMeeting/7IMB_Report_EN.pdf
14. CDC. Certification of poliomyelitis eradication – the Americas, 1994. MMWR Morb Mortal Wkly Rep. 1994; 43 (39): 720 – 722.
15. CDC. Certification of poliomyelitis eradication – the Western Pacific region, October 2000. MMWR Morb Mortal Wkly Rep. 2001; 50 (1): 1– 3.
16. CDC. Certification of poliomyelitis eradication – European Region, June 2002. MMWR Morb Mortal Wkly Rep. 2002; 51 (26): 572 – 574.
17. Bahl S., Kumar R., Menabde N., Thapa A., McFarland J., Swezy V. et al. Polio-free certification and lessons learned – South-East Asia. MMWR Morb Mortal Wkly Rep. 2014; 63 (42): 941 – 946.
18. WHO. Risk assessment: frequency and burden of VAPP, cVDPV and iVDPV. Report of the interim meeting of the Technical Consultative Group (TCG) on the Global Eradication of Poliomyelitis: Geneva, 13–14 November 2002. Geneva: WHO; 2002.
19. Platt L.R., Estivariz C.F., Sutter R.W. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J. Infect. Dis. 2014; 210 (1): 380 – 389.
20. Ivanova O.E., Ereemeeva T.P., Leshchinskaya E.V., Korotkova E.A., Yakovenko M.L., Chernyavskaya O.P. et al. Paralytic poliomyelitis in Russian Federation in 1998–2005. Zh. Microbiol. Epidemiol. Immunobiol. 2007; 5: 37 – 44 (in Russian).
21. Prevots D.R., Sutter R.W., Strebel P.M., Weibel R.E., Cochi S.L. Completeness of reporting for paralytic poliomyelitis, United States, 1980 through 1991. Arch. Pediatr. Adolesc. Med. 1994; 148 (5): 479 – 485.
22. Alexander L.N., Seward J.F., Santibanzas T.A., Pallansch M.A., Kew O.M., Prevots D.R. et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA. 2004; 292 (14): 1696 – 1701.
23. WHO. Polio vaccines and polio immunization in the pre-eradication era: WHO position paper. Wkly Epidemiol. Rec. 2010; 85 (23): 213 – 228.
24. Strebel P.M., Sutter R.W., Cochi S.L., Biellik R.J., Brink E.W., Kew O.M. et al. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin. Inf. Dis. 1992; 14 (2): 568 – 579.
25. Order of the Ministry of Health of the Russian Federation № 673 of 30.10.2007 «On Amendments to the Order of Ministry of Health of Russia on June 27, 2001 № 229 «On the national calendar of preventive vaccinations and calendar of preventive vaccination on epidemic indications». Available at: <http://www.garant.ru/products/ipo/prime/doc/4085698/> (in Russian).
26. Ivanova O.E., Ereemeeva T.P., Yakovenko M.L., Gmyl' A.P., Shakaryan A.K., Baykova O.Yu. et al. Vaccine-associated paralytic poliomyelitis in the Russian Federation and the current vaccination strategies. Materials of the International Conference «Molecular epidemiology of actual infections», Saint-Petersburg, 5 – 7 June 2013. Infection and Immunity. 2013; 3 (2): 97 – 196 (in Russian).
27. Kew O.M., Sutter R.W., de Gourville E.M., Dowdle W.R., Pallansch M.A. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu. Rev. Microbiol. 2005; 59: 587 – 635.
28. Diop U., Burns C., Wassilak S., Kew O. Update on Vaccine-Derived Polioviruses – Worldwide, July 2012–December 2013. MMWR Morbid Mortal Wkly Rep. 2014; 63 (11): 242 – 248.
29. Wassilak S., Pate M.A., Wannemuehler K., Jenks J., Burns C., Chenoweth P. et al. Outbreak of type 2 vaccine-derived poliovirus in Nigeria: emergence and widespread circulation in an underimmunized population. J. Infect. Dis. 2011; 203: 898 – 909.
30. Yang C., Naguib T., Yang S., Nasr S., Jorba J., Ahmed N. et al. Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 – 1993. J. Virol. 2003; 77 (15): 8366 – 8377.
31. CDC. Circulation of a type 2 vaccine-derived poliovirus – Egypt, 1982–1993. MMWR Morbid Mortal Wkly Rep. 2001; 50 (3): 41 – 42.
32. CDC. Update on vaccine-derived polioviruses – worldwide, April 2011–June 2012. MMWR Morbid Mortal Wkly Rep. 2012; 61 (37): 741 – 746.
33. Nathanson N., Kew O.M. From emergence to eradication: the epidemiology of poliomyelitis deconstructed. Am. J. Epidemiol. 2010; 172 (11): 1213 – 1229.
34. CDC. Laboratory surveillance for wild and vaccine-derived polioviruses – worldwide, January 2008–June 2009. MMWR Morb Mortal Wkly Rep; 2009; 58 (34): 950 – 954.
35. DeVries A.S., Harper J., Murray A., Lexau C., Bahta L., Christensen J. et al. Vaccine-derived poliomyelitis 12 years after infection in Minnesota. N. Engl. J. Med. 2011; 364 (24): 2316 – 2323.
36. Sutter R.W., Prevots D.R. Vaccine-associated paralytic poliomyelitis among immunodeficient persons. Infect. Med. 1994; 11: 426 – 438.
37. Khetsuriani N., Prevots D.R., Quick L., Elder M.E., Pallansch M., Kew O., Sutter R.W. Persistence of vaccine-derived polioviruses among immunodeficient persons with vaccine-associated paralytic poliomyelitis. J. Infect. Dis. 2003; 188 (12): 1845 – 1852.
38. Halsey N.A., Pinto J., Espinosa-Rosales F., Faure-Fontenla M.A., da Silva E., Khan A.J. et al. Search for poliovirus carriers among people with primary immune deficiency diseases in the United States, Mexico, Brazil, and the United Kingdom. Bull. of the WHO. 2004; 82 (1): 3 – 8.
39. Khan A.J., Gebreselassie H., Asturias E.J., Agboatwalla M., Teklehaimanot R., Luby S.P. et al. No evidence for prolonged excretion of polioviruses in persons with residual paralytic poliomyelitis in Ethiopia, Pakistan and Guatemala. Biologicals. 2006; 34 (2): 113 – 116.
40. Li L., Ivanova O., Driss N., Tiongo-Recto M., da Silva R., Shahmahmoodi S. et al. Poliovirus excretion among persons with primary immune deficiency disorders: summary of a seven-country study series. J. Infect. Dis. 2014; 210 (1): 368 – 372.
41. Pavlov D.N., Van Zyl W.B., van Heerden J., Kruger M., Blignaut L., Grabow W.O. et al. Prevalence of vaccine-derived polioviruses in stools of immunodeficient children in South Africa. J. Appl. Microbiol. 2006; 101 (6): 1367 – 1379.
42. de Silva R., Gunasena S., Ratnayake D., Wickremesinghe G.D., Kumarasiri C.D., Pushpakumara B.A. et al. Prevalence of prolonged and chronic poliovirus excretion among persons with primary immune deficiency disorders in Sri Lanka. Vaccine. 2012; 30 (52): 7561 – 7565.
43. Triki H., Barbouche M.R., Bahri O., Bejaoui M., Dellagi K. Community-acquired poliovirus infection in children with primary immunodeficiency in Tunisia. J. Clin. Microbiol. 2003; 41 (3): 1203 – 1211.
44. Al-Hello H., Jorba J., Blomqvist S., Raud R., Kew O., Roivainen M. Highly divergent types 2 and 3 vaccine-derived polioviruses isolated from sewage in Tallinn, Estonia. J. Virol. 2013; 87 (23): 13076 – 13080.
45. WHO. Meeting of the Strategic Advisory Group of Experts on immunization, November 2012 – conclusions and recommendations. Wkly Epidemiol. Rec. 2013; 88 (1): 1 – 16.
46. WHO. Polio Eradication and Endgame Strategic Plan 2013 – 2018. Available at: http://www.polioeradication.org/Portals/0/Document/Resources/StrategyWork/PEESP_EN_A4.pdf
47. Sutter R.W., John T.J., Jain H., Agarkhedkar S., Ramanan P.V., Verma H. et al. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial. Lancet. 2010; 376 (9753): 1682 – 1688.
48. O'Reilly K.M., Durr E., ul Islam O., Ouddus A., Abid N., Mir T.P. et al. The effect of mass immunisation campaigns and new oral poliovirus vaccines on the incidence of poliomyelitis in Pakistan and Afghanistan, 2001 – 2011: a retrospective analysis. Lancet. 2012; 380 (9840): 491 – 498.
49. Cochi S.L., Jafari H.S., Armstrong G.L., Sutter R.W., Linkins R.W., Pallansch M.A. et al. A world without polio. J. Infect. Dis. 2014; 210 (1): 1 – 4.
50. Burns C.C., Diop O.M., Sutter R.W., Kew O.M. Vaccine-derived polioviruses. J. Infect. Dis. 2014; 210 (1): 283 – 293.
51. McKinlay M., Collett M., Hincks J., Oberste S., Pallansch M., Okayasu H. et al. Progress in the development of poliovirus antiviral agents and their essential role in reducing risks that threaten eradication. J. Infect. Dis. 2014; 210 (1): 447 – 453.

КОРОТКОЙ СТРОКОЙ

ВОЗ опубликовала свое первое в истории Руководство по профилактике, лечению и уходу за лицами, живущими с хроническим гепатитом В (ХГВ), – «WHO guidelines for the prevention, care and treatment of persons living with chronic hepatitis B infection».

Представляя издание, д-р Штефан Виктор (Dr. Stefan Wiktor, руководящий восточной Глобальной программой по борьбе с вирусными гепатитами) сказал, что лечение гепатита В зависит от целого ряда факторов и что в новом Руководстве

изложены простые и доступные рекомендации по лечению и они должны помочь врачам принимать правильные решения.

Руководство охватывает весь спектр медицинской помощи, необходимой страдающему ХГВ, – от определения того, кто нуждается в лечении, какие лекарства использовать и как наблюдать людей с ХГВ в долгосрочной перспективе.

Источник: <http://www.who.int/mediacentre/news/releases/2015/hepatitis-b-guideline/en/>